Osteosarcoma

From Wikipedia, the free encyclopedia

**Osteosarcoma**
*Classifications and external resources*
ICD-10	C 40.-C 41.
ICD-9	170
ICD-O:	M 9180/3

Osteosarcoma is the most common type of malignant bone cancer, accounting for 35% of primary bone malignancies. There is a preference for the metaphyseal region of tubular long bones. 50% of cases occur around the knee. It is a malignant connective (soft) tissue tumor whose neoplastic cells present osteoblastic differentiation and form tumoral bone.

1 Prevalence
2 Pathology
3 Causes
4 Symptoms
5 Diagnosis
6 Treatment
7 Prognosis
8 Canine Osteosarcoma
9 References
10 External links

[edit] Prevalence

Terry Fox (1981) - Began a run across Canada to raise money for cancer research - He developed Osteosarcoma as a teenager and had a leg amputated. Today the Terry Fox Run continues to raise money for cancer research. Through the money raised by the fundraising runs major improvements were made in the treatment of the cancer. Today amputations are rare.

It is the 6th leading cancer in children under age 15. Osteosarcoma affects 400 children under age 20 and 500 adults (most between the ages of 15-30) every year in the USA. Approximately 1/3 of the 900 will die each year, or about 300 a year. A second peak in incidence occurs in the elderly, usually associated with an underlying bone pathology such as Paget's disease, medullary infarct, or prior irradiation. Although about 90% of patients are able to have limb-salvage surgery, complications, such as infection, prosthetic loosening and non-union, or local tumor recurrence may cause the need for further surgery or amputation.

[edit] Pathology

The tumor may be localized at the end of the long bones. Most often it affects the upper end of tibia or humerus, of lower end of femur. The tumor is solid, hard, irregular ("fir-tree" or "sun-burst" appearance on X-ray examination) due to the tumor spicules of calcified bone radiating in right angles. These right angles form what is known as Codman's triangle. Surrounding tissues are infiltrated.

Microscopically: The characteric feature of osteosarcoma is presence of osteoid (bone formation) within the tumour. Tumor cells are very pleomorphic (anaplastic), some are giant, numerous atypical mitoses. These cells produce osteoid describing irregular trabeculae (amorphous, eosinophilic/pink) with or without central calcification (hematoxylinophilic/blue, granular) - tumor bone. Tumor cells are included in the osteoid matrix. Depending on the features of the tumour cells present (whether they resemble bone cells, cartilage cells or fibroblast cells), the tumour can be subclassified. Presence of immature blood vessels (sarcomatous vessels lacking endothelial cells) favors the bloodstream metastasizing. 1

[edit] Causes

The causes of osteosarcoma are not known. Due to the rarity of osteosarcoma, it appears that a genetic predisposition exists which renders some individuals vulnerable to developing the condition. Questions remain about whether radium , or fluoride, in drinking water can act as "environmental triggers" for increasing the incidence of the disease.

[edit] Symptoms

Many patients first complain of pain that may be worse at night and may have been occurring for some time. If the tumour is large, it can appear as a swelling. The affected bone is not as strong as normal bones and may fracture with only minor trauma (a pathological fracture).

[edit] Diagnosis

Family physicians and orthopedists rarely see a malignant bone tumor (most bone tumors are benign). Thus, many patients are initially misdiagnosed with cysts or muscle problems, and some are sent straight to physical therapy without an x-ray.

The route to osteosarcoma diagnosis usually begins with an x-ray, continues with a combination of scans (CT scan, PET scan, bone scan, MRI) and ends with a surgical biopsy. Much can be seen on films, but the biopsy is the only definitive proof that a bone tumor is indeed malignant or benign.

The biopsy of suspected osteosarcoma should be performed by a qualified orthopedic oncologist. The American Cancer Society states: "Probably in no other cancer is it as important to perform this procedure properly. An improperly performed biopsy may make it difficult to save the affected limb from amputation."

[edit] Treatment

Patients with this are best managed by an oncologist and an orthopedic oncologist experienced in managing sarcomas. Current standard treatment is to use neoadjuvant chemotherapy (chemotherapy given before surgery) followed by surgical resection. The percentage of tumor cell necrosis (cell death) seen in the tumor after surgery gives an idea of the prognosis and also lets the oncologist know if the chemotherapy regime should be altered after surgery.

Standard therapy is a combination of limb-salvage orthopaedic surgery and a combination of high dose methotrexate with leucovorin rescue, intra-arterial cisplatin (with or without caffeine, practiced in Japan), adriamycin, ifosfamide with mesna, BCD, etoposide, muramyl tri-peptite (MTP).

Ifosfamide can be used as an adjuvant treatment if the necrosis rate is low.

3-year event free survival ranges from 50% to 75%. and 5-year survival ranges from 60% to 85+% in some studies. Overall, 60-65% treated 5-years ago (2000) will be alive today. Osteosarcoma has one of the lowest survival rates for pediatric cancer despite chemotherapy's success in osteosarcoma of 6 chemotherapies, interferon-alpha, interleukin-2, and being the prototype of solid tumors in cancer.

Treatment studies come from Children's hospital Boston, Memorial Sloan-Kettering, Children's Oncology Group, Italian Oncology Group, Japan, and MD Anderson in Texas.

Fluids are given for hydration.

Drugs like Krytril and Zofran help with nausea and vomiting.

Neupogen, epogen, Neulasta help with white blood cell counts and neutrophil counts.

Blood helps with anemia.

[edit] Prognosis

Prognosis is separted into three groups.

Stage I osteosarcoma is rare and includes parosteal osteosarcoma or low-grade central osteosarcoma. It has an excellent prognosis (>90%) with wide resection.

Stage IIb prognosis depends on the site of the tumor (proximal tibia, femur, pelvis, etc.) size of the tumor mass (in cm.), the degree of necrosis from neoadjuvant chemotherapy (beforeoperation chemotherapy), and pathological factors like the degree of p-glycoprotein, whether your tumor is CXCR4 positive, Her2 positive as these can lead to distant metastases to the lung. Longer time to metastases, more than 12 months or 24 months and the number of metastases and resectability of them lead to the best prognosis with metastatic osteosarcoma. It is better to have fewer metastases than longer time to metastases. Those with a longer length of time(>24months) and few nodules (2 or fewer) have the best prognosis with a 2-year survival after the metastases of 50% 5-year of 40% and 10 year 20%. If metastases are both local and regional the prognosis is different unfortunately. (see http://www.osteosarcomasupport.org/prognosis.htm) top two articles.

Initial Presentation of stage III osteosarcoma with lung metastates depends on the resectability of the primary tumor and lung nodules, degree of necrosis of the primary tumor, and maybe the number of metastases. Overall prognosis is 30% or greater depending.

[edit] Canine Osteosarcoma

Osteosarcoma is the most common bone tumor in dogs and typically afflicts older large and giant breed dogs (for example, Greyhounds, German Shepherds, and Great Danes). It has a ten times greater incidence in dogs than humans.^[1] The most commonly affected bones are the humerus, the radius, the femur, and the tibia.^[2] Other sites include the ribs, the mandible, the spine, and the pelvis. Metastasis of tumors involving the limb bones is very common, usually to the lungs. The tumor causes a great deal of pain, and can even lead to fracture of the affected bone. Amputation of the leg is the initial treatment, although this alone will not prevent metastasis. Chemotherapy combined with amputation improves the survival time, but most dogs still die within a year.^[2] There are surgical techniques designed to save the leg, but they do not improve the prognosis. One key difference between osteosarcoma in dogs and humans is that the cancer is far more likely to spread to the lungs in dogs.

Osteosarcoma is also the most common bone tumor in the cat and most commonly affects the rear leg. The cancer is less aggressive in cats than in dogs, and therefore amputation alone can lead to a significant survival time.^[2]

[edit] References

^ Withrow, S.J. (2003). Limb Sparing Trials and Canine Osteosarcoma. Genes, Dogs and Cancer: 3rd Annual Canine Cancer Conference, 2003. Retrieved on 2006-06-16.
^ ^a ^b ^c Morrison, Wallace B. (1998). Cancer in Dogs and Cats, 1st ed., Williams and Wilkins. ISBN 0-683-06105-4.